The online booking platform aims to streamline scheduling for everything from virtual appointments to workshops.
This blog will explore the importance, features, benefits, challenges, and future trends associated with pharmacy delivery software. Whether you’re a pharmacy owner, healthcare provider ...
・The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. ・Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin ...
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...
Amicus Therapeutics (FOLD) reported Q3 results that caught investors’ attention, posting GAAP profitability along with solid revenue gains from its rare disease therapies. Global expansion and ...
Courtly Observations is a recurring series by Erwin Chemerinsky that focuses on what the Supreme Court’s decisions will mean for the law, for lawyers and lower courts, and for people’s lives. Please ...
The Supreme Court is, apparently, reading its amicus briefs — and one of them may provide an offramp from immediately having to decide whether President Trump has the power to deploy the National ...
Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision ...
For years, we've all driven by the "big green round thing" — as our kids like to call it — in Downtown Tallahassee and wondered, "Is anything ever gonna go in the Old City Waterworks building? Seems ...
Historian Jill Lepore explains how the power to change the law through constitutional amendments was always intended to keep Americans from killing each other. We're ...
In this week’s bonus episode of Amicus Plus, Dahlia Lithwick and Richard L. Hasen discuss the current state of voting rights in the U.S., focusing on the implications of potential changes to Section 2 ...